SI2915564T1 - Antidoti za zaviralce dejavnika Ksa in postopki njihove uporabe - Google Patents

Antidoti za zaviralce dejavnika Ksa in postopki njihove uporabe

Info

Publication number
SI2915564T1
SI2915564T1 SI200832153T SI200832153T SI2915564T1 SI 2915564 T1 SI2915564 T1 SI 2915564T1 SI 200832153 T SI200832153 T SI 200832153T SI 200832153 T SI200832153 T SI 200832153T SI 2915564 T1 SI2915564 T1 SI 2915564T1
Authority
SI
Slovenia
Prior art keywords
antidotes
inhibitors
factor
methods
same
Prior art date
Application number
SI200832153T
Other languages
English (en)
Slovenian (sl)
Inventor
Genmin Lu
David R. Phillips
Patrick Andre
Uma Sinha
Original Assignee
Alexion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals, Inc. filed Critical Alexion Pharmaceuticals, Inc.
Publication of SI2915564T1 publication Critical patent/SI2915564T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
SI200832153T 2007-09-28 2008-09-26 Antidoti za zaviralce dejavnika Ksa in postopki njihove uporabe SI2915564T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97634307P 2007-09-28 2007-09-28
US9057408P 2008-08-20 2008-08-20
EP14197779.3A EP2915564B1 (en) 2007-09-28 2008-09-26 Antidotes for factor XA inhibitors and methods of using the same

Publications (1)

Publication Number Publication Date
SI2915564T1 true SI2915564T1 (sl) 2021-03-31

Family

ID=40481812

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200832153T SI2915564T1 (sl) 2007-09-28 2008-09-26 Antidoti za zaviralce dejavnika Ksa in postopki njihove uporabe
SI200832130T SI3078743T1 (sl) 2007-09-28 2008-09-26 Antidoti za zaviralce dejavnika Xa in postopki njihove uporabe
SI200831678A SI2193196T1 (sl) 2007-09-28 2008-09-26 Antidoti za inhibitor faktorja Xa in postopki njegove uporabe

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200832130T SI3078743T1 (sl) 2007-09-28 2008-09-26 Antidoti za zaviralce dejavnika Xa in postopki njihove uporabe
SI200831678A SI2193196T1 (sl) 2007-09-28 2008-09-26 Antidoti za inhibitor faktorja Xa in postopki njegove uporabe

Country Status (26)

Country Link
US (8) US8153590B2 (cg-RX-API-DMAC7.html)
EP (4) EP3824902A1 (cg-RX-API-DMAC7.html)
JP (7) JP5637561B2 (cg-RX-API-DMAC7.html)
KR (4) KR102069498B1 (cg-RX-API-DMAC7.html)
CN (4) CN102559644B (cg-RX-API-DMAC7.html)
AU (7) AU2008304192B9 (cg-RX-API-DMAC7.html)
BR (2) BR122022001846B1 (cg-RX-API-DMAC7.html)
CA (1) CA2697583C (cg-RX-API-DMAC7.html)
CY (3) CY1118482T1 (cg-RX-API-DMAC7.html)
DK (3) DK3078743T3 (cg-RX-API-DMAC7.html)
ES (3) ES2796623T3 (cg-RX-API-DMAC7.html)
FR (1) FR20C1045I2 (cg-RX-API-DMAC7.html)
HR (2) HRP20161255T1 (cg-RX-API-DMAC7.html)
HU (4) HUE052423T2 (cg-RX-API-DMAC7.html)
IL (4) IL203993A (cg-RX-API-DMAC7.html)
LT (3) LT3078743T (cg-RX-API-DMAC7.html)
MX (1) MX2010003095A (cg-RX-API-DMAC7.html)
NL (1) NL301063I2 (cg-RX-API-DMAC7.html)
NO (2) NO2019040I1 (cg-RX-API-DMAC7.html)
NZ (1) NZ583944A (cg-RX-API-DMAC7.html)
PL (3) PL2193196T3 (cg-RX-API-DMAC7.html)
PT (3) PT3078743T (cg-RX-API-DMAC7.html)
SG (1) SG185263A1 (cg-RX-API-DMAC7.html)
SI (3) SI2915564T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009042962A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA201002039B (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
EP3824902A1 (en) * 2007-09-28 2021-05-26 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
CN102316893B (zh) * 2008-11-14 2015-02-18 博尔托拉制药公司 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
US8450275B2 (en) 2010-03-19 2013-05-28 Baxter International Inc. TFPI inhibitors and methods of use
DK2379096T3 (da) 2008-12-19 2019-11-25 Baxalta GmbH TFPI-inhibitorer og fremgangsmåder til anvendelse
LT3604510T (lt) * 2009-03-30 2025-07-10 Alexion Pharmaceuticals, Inc. Faktoriaus xa inhibitorius neutralizuojančios medžiagos ir jų naudojimo būdai
PT2453910T (pt) * 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
ES2620421T3 (es) * 2009-10-30 2017-06-28 Senova Gesellschaft für Biowissenschaft und Technik mbH Peptidasas acopladas a polímero
US8742120B2 (en) * 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
US8530501B2 (en) * 2009-12-17 2013-09-10 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor Xa inhibitor
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
TW201240664A (en) * 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
TW201221128A (en) 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
US20140050743A1 (en) * 2011-01-19 2014-02-20 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
FR2972114B1 (fr) * 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
PE20140964A1 (es) 2011-03-30 2014-08-17 Boehringer Ingelheim Int Antidotos anticoagulantes
WO2013049804A1 (en) * 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
AR089020A1 (es) * 2011-11-29 2014-07-23 Perosphere Inc Agentes de reversion anticoagulante
HK1205188A1 (en) 2012-02-14 2015-12-11 Portola Pharmaceuticals, Inc. Process for making recombinant antidote to factor xa inhibitor
WO2013123248A1 (en) 2012-02-16 2013-08-22 Portola Pharmaceuticals, Inc. MODULATION OF FACTOR Xa INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE
SI2827883T1 (sl) 2012-03-21 2019-08-30 Baxalta GmbH Inhibitorji TFPI in postopki uporabe
SG11201408028YA (en) * 2012-06-14 2015-01-29 Portola Pharm Inc METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES
IN2015DN01404A (cg-RX-API-DMAC7.html) 2012-07-25 2015-07-03 Catalyst Biosciences Inc
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
FR3000895B1 (fr) * 2013-01-11 2017-02-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques
EP2948168B1 (en) * 2013-01-24 2018-07-18 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
HK1215196A1 (zh) * 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
FR3007410B1 (fr) * 2013-06-21 2016-05-27 Lab Francais Du Fractionnement Facteur x depourvu de domaine gla
SG11201601221XA (en) * 2013-09-24 2016-04-28 Pfizer Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
WO2015066606A2 (en) * 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
MA40042B1 (fr) * 2014-05-26 2020-08-31 Academisch Ziekenhuis Leiden Protéines prohémostatiques pour le traitement de saignement
JP6776221B2 (ja) * 2014-07-31 2020-10-28 ヘモネティクス・コーポレーションＨａｅｍｏｎｅｔｉｃｓ Ｃｏｒｐｏｒａｔｉｏｎ 凝固分析を使用した抗凝固剤の検出および分類
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
KR20250150675A (ko) * 2014-08-20 2025-10-20 포톨라 파마슈티컬스, 인코포레이티드 인자 xa 해독제용 동결건조된 제형
CN105030703B (zh) * 2015-06-23 2018-03-23 上海旭东海普药业有限公司 一种防治疗栓塞性疾病的利伐沙班片及其制备方法
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
CN108883160B (zh) * 2016-02-24 2022-06-28 博尔托拉制药公司 因子xa解毒剂的冻干制剂
US10859562B2 (en) 2016-02-29 2020-12-08 Iridia, Inc. Methods, compositions, and devices for information storage
US10640822B2 (en) 2016-02-29 2020-05-05 Iridia, Inc. Systems and methods for writing, reading, and controlling data stored in a polymer
EP3423597A4 (en) * 2016-02-29 2020-03-04 Iridia, Inc. METHODS, COMPOSITIONS AND DEVICES FOR STORING INFORMATION
US10438662B2 (en) 2016-02-29 2019-10-08 Iridia, Inc. Methods, compositions, and devices for information storage
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
CN116425860B (zh) 2016-06-17 2025-03-04 阿雷克森制药公司 因子xa衍生物的制备
WO2018115235A1 (en) 2016-12-22 2018-06-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antidotes to anti-coagulant drugs allowing diagnosis and treatment
US11168147B2 (en) 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019040532A1 (en) * 2017-08-21 2019-02-28 Allele Biotechnology & Pharmaceuticals, Inc. LIGHT-ABSORBING COMPOSITIONS AND METHODS OF USE
ES3050257T3 (en) 2017-11-15 2025-12-19 Novo Nordisk As Factor x binders enhancing fx activation
JP2021527435A (ja) * 2018-06-19 2021-10-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤に対する解毒剤
WO2020034989A1 (zh) * 2018-08-14 2020-02-20 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
WO2020163685A1 (en) * 2019-02-07 2020-08-13 Portola Pharmaceuticals, Inc. Methods for treating intracranial hemorrhage and assessing efficacy
US11655465B1 (en) 2019-05-02 2023-05-23 Iridia, Inc. Enzymes and systems for synthesizing DNA
ES3033092T3 (en) 2019-08-08 2025-07-30 Alexion Pharma Inc Compositions and methods for preparing factor xa and derivatives
JP2023530313A (ja) * 2020-06-16 2023-07-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アンデキサネットの効力を試験するための方法
US11837302B1 (en) 2020-08-07 2023-12-05 Iridia, Inc. Systems and methods for writing and reading data stored in a polymer using nano-channels
EP3971576B1 (en) 2020-09-21 2025-03-19 Instrumentation Laboratory Company Detecting and monitoring oral anticoagulants or intravenous direct thrombin inhibitors in a blood sample
CN113484386B (zh) * 2021-05-21 2024-02-13 郑州轻工业大学 一种金属聚酞菁纳米材料的制备方法及其应用，适配体传感器及其制备方法
CN114681597A (zh) * 2022-03-11 2022-07-01 兆科药业（合肥）有限公司 蝰蛇蛇毒血凝酶在制备用于逆转凝血因子Xa抑制剂的抗凝作用的药物中的应用
CN116327627B (zh) * 2023-03-10 2024-06-07 四川大学 一种四面体框架核酸-光甘草定复合物及其在皮肤美白方面的用途

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH596313A5 (cg-RX-API-DMAC7.html) * 1975-05-30 1978-03-15 Battelle Memorial Institute
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3546806C2 (cg-RX-API-DMAC7.html) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5686073A (en) 1990-05-23 1997-11-11 The University Of Iowa Research Foundation Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
US5278144A (en) 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
RO116199B1 (ro) 1991-09-13 2000-11-30 Chiron Corp Compozitie polipeptidica hcv imunogena
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
JPH07507769A (ja) 1992-03-20 1995-08-31 コアー・セラピュティックス・インコーポレーテッド Ｘ因子のグリコシル化媒介による阻害
DE69434486T2 (de) 1993-06-24 2006-07-06 Advec Inc. Adenovirus vektoren für gentherapie
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
BR9407956A (pt) 1993-10-25 1996-11-26 Canji Inc Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
DE4430205A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US5589571A (en) 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US6709659B1 (en) 1996-08-02 2004-03-23 Zymogenetics, Inc. Antibodies that bind testis-specific insulin homolog polypeptides
SE9604744D0 (sv) 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A modified coagulation agent
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT405517B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AU6673898A (en) * 1997-03-07 1998-09-22 Washington University Factor x variant
JPH1149800A (ja) 1997-06-05 1999-02-23 Fujimori Kogyo Kk アンヒドロトロンビンの合成方法
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US6858599B2 (en) 1999-06-30 2005-02-22 Mochida Pharmaceutical Co., Ltd. Tricyclic compound having spiro union
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
ATE311366T1 (de) 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
CN1452633A (zh) 2000-09-08 2003-10-29 先灵公司 哺乳动物基因、相关试剂及方法
US7070740B1 (en) 2000-09-28 2006-07-04 Beckman Coulter, Inc. Method and apparatus for processing biomolecule arrays
US20030064414A1 (en) 2001-03-30 2003-04-03 Benecky Michael J. Rapid assessment of coagulation activity in whole blood
US7138506B2 (en) 2001-05-09 2006-11-21 Genetic Id, Na, Inc. Universal microarray system
US6989267B2 (en) 2001-07-02 2006-01-24 Agilent Technologies, Inc. Methods of making microarrays with substrate surfaces having covalently bound polyelectrolyte films
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
US20040198660A1 (en) 2002-11-06 2004-10-07 Petersen Lars Christian Tissue factor antagonist and protein C polypeptide compositions
US7247654B2 (en) 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
EP1723422A2 (en) 2004-03-05 2006-11-22 The Scripps Research Institute High throughput glycan microarrays
JP4441336B2 (ja) 2004-06-11 2010-03-31 日本碍子株式会社 マイクロアレイの製造方法
US9223929B2 (en) 2005-03-14 2015-12-29 The California Institute Of Technology Method and apparatus for detection, identification and quantification of single-and multi-analytes in affinity-based sensor arrays
US7119179B1 (en) 2005-03-21 2006-10-10 Los Alamos National Security, Llc Preparation of high nitrogen compound and materials therefrom
WO2006102687A1 (en) 2005-03-22 2006-09-28 The Trustees Of Columbia University In The City Of New York A liposome-based microarray and methods of use thereof
US7598276B2 (en) 2005-11-08 2009-10-06 Millenium Pharmaceuticals, Inc. Pharmaceutical salts and polymorphs of a factor Xa inhibitor
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
US20070111322A1 (en) 2005-11-15 2007-05-17 Lin-Cheng Yang Novel method of using inject printing for creating microarrays
EP1820508A1 (en) * 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
EP3824902A1 (en) * 2007-09-28 2021-05-26 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
CN102316893B (zh) 2008-11-14 2015-02-18 博尔托拉制药公司 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
CN104262479A (zh) 2008-12-19 2015-01-07 国家健康与医学研究院 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途
LT3604510T (lt) * 2009-03-30 2025-07-10 Alexion Pharmaceuticals, Inc. Faktoriaus xa inhibitorius neutralizuojančios medžiagos ir jų naudojimo būdai
PT2453910T (pt) * 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento

Also Published As

Publication number Publication date
NL301063I2 (nl) 2021-06-23
US20090098119A1 (en) 2009-04-16
US11839646B2 (en) 2023-12-12
NO2020033I1 (no) 2020-09-23
KR20160025038A (ko) 2016-03-07
LT3078743T (lt) 2020-09-25
SI2193196T1 (sl) 2017-01-31
IL203993A0 (en) 2011-07-31
US20160354449A1 (en) 2016-12-08
WO2009042962A3 (en) 2009-06-04
HRP20161255T1 (hr) 2016-12-02
PT3078743T (pt) 2020-07-15
IL255397B (en) 2019-03-31
JP2017043632A (ja) 2017-03-02
CN101802188B (zh) 2013-08-21
MX2010003095A (es) 2010-04-09
IL272926A (en) 2020-04-30
AU2021218033A1 (en) 2021-09-09
HUE050063T2 (hu) 2020-11-30
US8889129B2 (en) 2014-11-18
AU2014210620A1 (en) 2014-08-28
CY1123504T1 (el) 2021-06-25
IL255397A0 (en) 2017-12-31
EP2915564A1 (en) 2015-09-09
US20200276280A1 (en) 2020-09-03
SI3078743T1 (sl) 2020-08-31
US20140079684A1 (en) 2014-03-20
EP2193196B1 (en) 2016-07-13
LT2193196T (lt) 2016-12-12
US10675335B2 (en) 2020-06-09
JP6047127B2 (ja) 2016-12-21
FR20C1045I1 (cg-RX-API-DMAC7.html) 2020-10-30
JP2014218521A (ja) 2014-11-20
HUS2000057I1 (hu) 2021-01-28
PL3078743T3 (pl) 2020-11-02
AU2013205326A8 (en) 2013-06-06
IL203993A (en) 2017-11-30
ZA201002039B (en) 2015-11-25
US20240082367A1 (en) 2024-03-14
WO2009042962A9 (en) 2009-09-11
JP2010539945A (ja) 2010-12-24
KR20200009131A (ko) 2020-01-29
EP3078743A1 (en) 2016-10-12
NL301063I1 (cg-RX-API-DMAC7.html) 2020-09-16
US20140044773A1 (en) 2014-02-13
EP2193196A2 (en) 2010-06-09
CN102559644A (zh) 2012-07-11
US8153590B2 (en) 2012-04-10
CN102533702A (zh) 2012-07-04
CN103446579B (zh) 2015-04-22
CY2020042I2 (el) 2021-06-25
CY1118482T1 (el) 2017-07-12
PL2915564T3 (pl) 2021-07-19
HUE031647T2 (en) 2017-07-28
KR101698214B1 (ko) 2017-01-20
LTPA2020540I1 (lt) 2021-01-11
CN103446579A (zh) 2013-12-18
JP2022153574A (ja) 2022-10-12
LTC3078743I2 (lt) 2022-06-10
AU2008304192A2 (en) 2010-04-08
IL264886B (en) 2020-03-31
US8455441B2 (en) 2013-06-04
WO2009042962A2 (en) 2009-04-02
KR20170100071A (ko) 2017-09-01
CA2697583A1 (en) 2009-04-02
BR122022001846B1 (pt) 2022-12-27
DK2193196T3 (en) 2016-11-07
SG185263A1 (en) 2012-11-29
EP2915564B1 (en) 2020-11-04
AU2008304192B2 (en) 2014-05-15
PT2193196T (pt) 2016-10-24
BRPI0816837A2 (pt) 2020-08-18
HRP20201071T1 (hr) 2020-10-30
ES2849426T3 (es) 2021-08-18
JP6300885B2 (ja) 2018-03-28
US9388401B2 (en) 2016-07-12
JP2018100290A (ja) 2018-06-28
US9062298B2 (en) 2015-06-23
NO2019040I1 (no) 2019-11-08
DK3078743T3 (da) 2020-08-10
DK2915564T3 (da) 2021-02-08
KR102069498B1 (ko) 2020-01-23
PL2193196T3 (pl) 2017-07-31
US20150057228A1 (en) 2015-02-26
AU2014210620B2 (en) 2016-05-12
BRPI0816837B1 (pt) 2022-10-18
AU2024287094A1 (en) 2025-01-16
AU2008304192A1 (en) 2009-04-02
AU2013205326A1 (en) 2013-05-09
PT2915564T (pt) 2021-02-09
JP2020109113A (ja) 2020-07-16
CN102559644B (zh) 2015-03-25
CY2020042I1 (el) 2021-06-25
ES2597436T3 (es) 2017-01-18
HK1210443A1 (en) 2016-04-22
AU2019204123A1 (en) 2019-07-04
CA2697583C (en) 2016-04-12
HUE052423T2 (hu) 2021-04-28
KR102271404B1 (ko) 2021-07-02
KR20100077172A (ko) 2010-07-07
EP3078743B1 (en) 2020-06-24
ES2796623T3 (es) 2020-11-27
CN101802188A (zh) 2010-08-11
AU2008304192B9 (en) 2024-02-01
JP5637561B2 (ja) 2014-12-10
ZA201406514B (en) 2016-10-26
NZ583944A (en) 2012-06-29
JP2025063249A (ja) 2025-04-15
FR20C1045I2 (fr) 2021-08-27
AU2017200212A1 (en) 2017-02-02
US20120269788A1 (en) 2012-10-25
EP3824902A1 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
HUS2000057I1 (hu) Az XA faktor inhibitorainak antidótumai és ezek felhasználási módszerei
SI3604510T1 (sl) Antidoti za zaviralce faktorja Xa in načini njihove uporabe
EP2200977A4 (en) F1F0-ATPASE INHIBITOR AND ASSOCIATED METHODS
ZA201101586B (en) Aminotriazolopyridines and their use as kinase inhibitors
ZA201004055B (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
ZA200809362B (en) Factor xa inhibitors
IL219646A0 (en) Novelnaphthyridine derivatives and the use thereof as kinase inhibitors
EP2224928A4 (en) NOVEL INHIBITORS OF SEH AND THEIR USE
ZA201002465B (en) Novel seh inhibitors and their use
ZA201103964B (en) 7-hydroxy-benzoimidazole-4-yl-methanone derivatives and pbk inhibitors containing the same
EP2217068A4 (en) NOVEL INHIBITORS OF SEH AND THEIR USE
EP2209376A4 (en) NEW SEH-HEMMER AND ITS USE
EP2240021A4 (en) NEW SEH-HEMMER AND ITS USE
EP2240026A4 (en) NEW SEE INHIBITORS AND THEIR USE
IL212700A0 (en) Novel pyrazolone-derivatives and their use as pd4 inhibitors
EP2240025A4 (en) NEW SEE INHIBITORS AND THEIR USE
EP2309859A4 (en) ENZYME INHIBITORS AND USE THEREOF
HK1139146A (en) Heterocyclic compounds and use thereof as erk inhibitors